Inscripta
Inscripta Acquires Infinome Biosciences, Sestina Bio
The acquisitions suggest that Inscripta has shifted its focus to biomanufacturing following dozens of layoffs across two site closures in December.
Inscripta Lays Off Dozens, Closes Colorado Headquarters, San Diego Office
The genome editing technology firm appears to be consolidating around its Pleasanton, California, office as it attempts to pivot its business.
Aldevron Gets License From Inscripta to Manufacture, Sell CRISPR Nuclease
The nuclease was released by Inscripta in 2017 free of charge to the research community and for single-digit royalties for commercial applications.
Penn State Licenses Genome Editing Tech to Inscripta
The new technology enables the simultaneous use of multiple guide RNAs and will be used with Inscripta's Onyx digital genome engineering platform.
Inscripta Licenses MAD7 CRISPR Nuclease to Hunterian Medicine
Hunterian, based in Cambridge, Massachusetts, said it plans to use MAD7 in its gene editing programs to develop human therapeutics.
Apr 5, 2021
Inscripta Closes $150M Series E Financing Round
Mar 30, 2021
Jan 22, 2020
Jan 7, 2020
Dec 10, 2019
Inscripta Raises $125M in Series D Financing Round
Oct 10, 2019
Sep 25, 2019
Mar 7, 2019
Aug 28, 2018